Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
Trial details
- Registry ID
- NCT06577090
- Drugs studied
- Nimacimab 300 mg injection, Nimacimab injection, semaglutide injection
TrialRedline tracks 2 clinical trials sponsored by Skye Bioscience, Inc.: 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs PlaceboNCT06577090 | Nimacimab 300 mg injection, Nimacimab injection, semaglutide injection | Active not recruiting | 2026-11-20Estimated |
| Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye PressureNCT06144918 | SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0% | Completed | 2024-02-22Actual |
Names as written in the registry records.
NCT06577090 · Skye Bioscience, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percent change in body weight (main study) Measure: Nature, frequency and severity of AEs (study extension) Measure: Part C - The nature, frequency, and severity of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs). After: Measure: Percent change in body weight (main study) Measure: Nature, frequency and severity of AEs (study extension).
Before: Estimated. After: Actual.
Before: 152 participants (planned). After: 136 participants (actual).
NCT06577090 · Skye Bioscience, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percent change in body weight. After: Measure: Percent change in body weight (main study) Measure: Nature, frequency and severity of AEs (study extension) Measure: Part C - The nature, frequency, and severity of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs).
Before: 120 participants (planned). After: 152 participants (planned).
Before: Aug 2025. After: 20 Nov 2026.